Provectus Biopharmaceuticals, Inc. financial data

Symbol
PVCT on OTC
Industry
Pharmaceutical Preparations
Location
800 S. Gay Street, Suite 1610, Knoxville, TN
State of incorporation
DE
Fiscal year end
December 31
Former names
PROVECTUS PHARMACEUTICALS INC (to 12/18/2013), PROVECTUS PHARMACEUTICAL INC (to 5/15/2002), ZAMAGE DIGITAL IMAGING INC (to 4/1/2002), SPM GROUP INC (to 11/14/2001)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 13.6 % -32.5%
Debt-to-equity -117 % +8.24%
Return On Equity 37.1 % -18.3%
Return On Assets -220 % -32.6%
Operating Margin -374 % -8.11%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 420M shares +0.09%
Common Stock, Shares, Outstanding 420M shares +0.01%
Entity Public Float 45.5M USD +102%
Common Stock, Value, Issued 420K USD +0.01%
Weighted Average Number of Shares Outstanding, Basic 420M shares +0.01%
Weighted Average Number of Shares Outstanding, Diluted 420M shares +0.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 684K USD -19.2%
Research and Development Expense 1.8M USD -4.73%
General and Administrative Expense 1.45M USD -23.5%
Operating Income (Loss) -2.56M USD +12.7%
Nonoperating Income (Expense) -229K USD -30.1%
Net Income (Loss) Attributable to Parent -2.79M USD +10.2%
Earnings Per Share, Basic -0.01 USD/shares 0%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.6K USD -83.2%
Assets, Current 800K USD -49.2%
Property, Plant and Equipment, Net 7.56K USD -54.1%
Operating Lease, Right-of-Use Asset 48.6K USD -48.7%
Assets 856K USD -49.2%
Accounts Payable, Current 1.32M USD -33.6%
Employee-related Liabilities, Current 2.05M USD -3.92%
Liabilities, Current 8.37M USD -6.31%
Operating Lease, Liability, Noncurrent 12.7K USD -79.4%
Liabilities 8.37M USD -6.84%
Accumulated Other Comprehensive Income (Loss), Net of Tax -60.5K USD -69%
Retained Earnings (Accumulated Deficit) -254M USD -1.11%
Stockholders' Equity Attributable to Parent -7.51M USD -2.96%
Liabilities and Equity 856K USD -49.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.04M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 781K USD +51.5%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 420M shares +0.01%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -264K USD -139%
Deferred Tax Assets, Valuation Allowance 47.3M USD +1.51%
Deferred Tax Assets, Gross 47.4M USD +1.51%
Operating Lease, Liability 50K USD -48.1%
Depreciation 2.23K USD +0.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.81M USD +9.45%
Lessee, Operating Lease, Liability, to be Paid 51.3K USD -49.3%
Operating Lease, Liability, Current 50K USD +8.11%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.7K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 25.7K USD -49.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.36K USD -73.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 25.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 41.9M USD -0.29%
Preferred Stock, Shares Authorized 25M shares 0%
Operating Lease, Payments 11.6K USD +8.36%
Additional Paid in Capital 246M USD +1.07%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%